Hims is stable and multi-condition. Lemonaid recently changed hands entirely.
Hims and Lemonaid Health are both multi-condition telehealth platforms that offer GLP-1 weight loss prescriptions as one of many services. Hims is a standalone publicly traded company (NYSE: HIMS) with a dedicated weight loss program and substantial operational infrastructure. Lemonaid Health has been through significant corporate upheaval: its former parent, 23andMe, filed for Chapter 11 bankruptcy in March 2025, and Lemonaid was sold separately — not as part of 23andMe's genetics-business sale to Regeneron — to Bambu Ventures and Innova Capital Partners for approximately $10 million in a deal completed in late 2025. Lemonaid now operates independently of 23andMe, but it is worth understanding that history before enrolling in a 12 to 18-month treatment program.
For patients who want the clinical simplicity of either platform but with flat-rate pricing, publicly verifiable pharmacy credentials, and a provider whose sole focus is GLP-1, Luma Health offers an alternative at $197/month flat for semaglutide and $297/month flat for tirzepatide — no contracts, no dose-tier increases, all 50 states.
The Lemonaid Health Situation: What Patients Need to Know
Before comparing Hims and Lemonaid Health on clinical merits, it is important to address the corporate history around Lemonaid Health directly — because for patients evaluating a GLP-1 provider they may rely on for 12 to 18 months, corporate stability is a genuine clinical consideration, not just a business footnote.
Lemonaid Health's Ownership Timeline
Lemonaid Health was founded in 2013 as a clinically focused telehealth platform offering primary-care-style physician visits for a range of conditions. It built a reputation for straightforward clinical interactions and transparent pricing.
In November 2021, 23andMe acquired Lemonaid Health for approximately $400 million, aiming to integrate Lemonaid's telehealth infrastructure with 23andMe's genetic data. In August 2024, Lemonaid launched a GLP-1 weight loss membership program under 23andMe ownership.
23andMe subsequently experienced severe corporate distress — a major 2023 data breach, a collapsing stock price, repeated layoffs, and board turmoil — culminating in a Chapter 11 bankruptcy filing in March 2025. In the bankruptcy proceedings, 23andMe's genetics and research business was sold to Regeneron Pharmaceuticals for $256 million, a deal that explicitly excluded Lemonaid Health. Lemonaid was sold separately, in a much smaller transaction, to Bambu Ventures and Innova Capital Partners for approximately $10 million — a steep markdown from the original $400 million purchase price — in a deal that closed in late 2025.
As of June 2026, Lemonaid Health operates independently of 23andMe under its new ownership and continues to offer a GLP-1 program, reportedly structured around a membership fee (historically around $49/month) with medication billed separately. Because the new ownership group is a small, less-established investor group rather than a large public company, its own long-term operational trajectory has not yet been tested over a multi-year period. Before enrolling with Lemonaid for a 12 to 18-month GLP-1 course, verify directly that their GLP-1 program is currently operating as advertised, confirm current pricing (which may differ from historical figures), and ask about their plans for program continuity under the new ownership.
Platform Deep Dive: Hims, Lemonaid Health, and Luma Health
Hims Publicly Traded (NYSE)
Hims & Hers Health (NYSE: HIMS) is one of the most recognized names in direct-to-consumer telehealth, built on a subscription model spanning hair loss, sexual health, skincare, mental health, and weight management. The company went public via SPAC merger in 2021 and has continued scaling its platform and product range aggressively since. Its weight loss program offers compounded semaglutide and tirzepatide through an async telehealth intake, with medication shipped by compounding pharmacy partners.
Hims' consumer-facing brand is polished and heavily marketed across digital, streaming, and traditional media channels. Patient reviews are broadly positive for the enrollment experience, though some patients report pricing confusion related to promotional rates that increase after the initial period and dose-tier escalation costs that exceed the advertised starting price.
✓ Strengths
- Stable, independent publicly traded company
- Strong brand recognition and consumer trust
- Established GLP-1 program with volume scale
- Competitive starting price ($79/mo)
- Well-designed platform and user experience
✗ Limitations
- Dose-tier pricing increases at maintenance
- Multi-category focus — not weight-loss-only
- Pharmacy not consistently named publicly
- Promotional rates can create bill shock
- Some plans require multi-month commitment
Lemonaid Health New Ownership (2025)
Lemonaid Health was founded with a clinically thoughtful approach to telehealth — physician-led consultations, straightforward pricing, and a primary-care model. This clinical orientation earned Lemonaid strong reviews among patients who wanted substantive medical interaction rather than a streamlined product purchase.
Following 23andMe's 2025 bankruptcy, Lemonaid was sold to a new private ownership group (Bambu Ventures and Innova Capital Partners). The clinical model has reportedly remained broadly intact under new ownership, and Lemonaid continues offering GLP-1 prescriptions as of June 2026. However, the company is now under new, less-established ownership with a shorter operating track record in this configuration — verifying current program availability, pricing, and continuity plans directly with Lemonaid before enrolling is essential.
✓ Strengths
- Historically strong clinical focus
- Primary-care-style provider interaction
- Competitive membership pricing
- Simpler platform with less upselling
- No longer tied to 23andMe's distress
✗ Limitations
- Recent change to new, smaller ownership group
- Long-term service continuity unproven under new owners
- Multi-condition generalist focus
- GLP-1 program details require direct verification
- Refund/cancellation policies reported as strict
Luma Health GLP-1 Focused
Luma Health is a GLP-1-focused telehealth provider offering compounded semaglutide and tirzepatide through a streamlined clinical intake model. Clinical services are provided by Wasef Health, PC. Medications are compounded by VialsRX, a 503A licensed sterile compounding pharmacy in Houston, TX (Texas State Board license #35264, publicly verifiable at pharmacy.texas.gov). Flat-rate pricing ($197/month for semaglutide, $297/month for tirzepatide) applies across all dose tiers with no contracts and free shipping to all 50 states.
Luma Health's distinguishing advantages relative to both Hims and Lemonaid are pricing predictability (flat rate that never changes with dose escalation), pharmacy transparency (publicly named, independently verifiable), and operational focus (GLP-1 is the only clinical area, not one of dozens).
✓ Strengths
- $197/mo flat — never increases with dose
- No contracts — month-to-month only
- Pharmacy named: VialsRX (TX #35264)
- Clinical provider named: Wasef Health, PC
- Free shipping, all 50 states
- Focused exclusively on GLP-1
✗ Limitations
- Higher starting price than Hims ($197 vs $79)
- Narrower service scope (GLP-1 only)
- Fewer public patient reviews than Hims
- No multi-condition platform for other needs
Three-Provider Side-by-Side Comparison
| Factor | Hims | Lemonaid Health | Luma Health |
|---|---|---|---|
| Sema monthly (start) | ~$79/mo | ~$49/mo membership + meds | $197/mo flat |
| Sema monthly (maintenance) | ~$149–$199/mo | Verify current pricing | $197/mo — no change |
| Tirzepatide price | ~$199–$329/mo | Verify directly | $297/mo flat |
| Dose-tier price increases | Yes | Verify directly | ✓ None |
| Contract requirement | Some plans | No long-term contract (reported) | ✓ None — month-to-month |
| Pharmacy publicly named | Not consistently | Not consistently | ✓ VialsRX, TX #35264 |
| Clinical provider named | General network | Physician-led (varies) | ✓ Wasef Health, PC |
| Corporate history | ✓ Independent public company | Sold out of 23andMe bankruptcy, 2025 | ✓ Independent, GLP-1 focused |
| Platform focus | Multi-condition | Primary care (general) | ✓ GLP-1 exclusively |
| Free shipping | Most plans | Reported 2–3 day delivery | ✓ Always — all 50 states |
| Insurance accepted | No (cash-pay) | No (cash-pay) | No (cash-pay) |
Who Each Provider Is Best For
The honest answer to "Hims or Lemonaid or something else?" depends on what you prioritize and what your treatment horizon looks like.
Choose Hims if you want the lowest possible starting price for the first one to two months of treatment ($79/month), a well-established multi-condition platform with strong brand recognition, and a stable, independently traded corporate structure. Hims is a legitimate first choice for patients who want brand familiarity and are comfortable with dose-tier pricing increases at maintenance.
Consider Lemonaid Health cautiously if you value a primary-care-style clinical interaction and Lemonaid's historically strong clinical reputation. The clinical model itself has real merit. The consideration is not clinical quality — it is that Lemonaid changed hands entirely in 2025 following its former parent's bankruptcy, and is now run by a smaller, newer ownership group with a shorter track record in this configuration. Before enrolling with Lemonaid for a 12 to 18-month GLP-1 course, contact their support team directly and ask specific questions: Is the GLP-1 program currently accepting new patients under the new ownership? What is the current membership fee and medication pricing? What is the refund and cancellation policy? Document the answers.
Choose Luma Health if you want flat-rate pricing certainty at all dose tiers, publicly verifiable pharmacy credentials, no contract commitment, and a provider focused exclusively on GLP-1. Luma's $197/month for semaglutide is comparable to Hims at maintenance doses while eliminating the dose-tier uncertainty entirely.
The Corporate Stability Checklist
Before enrolling with any GLP-1 telehealth provider for a long-term treatment course, these questions help assess whether the provider is stable enough to serve you through the full expected duration of treatment. They are relevant to Lemonaid Health given its recent ownership change, but they are also good practice for any provider in a rapidly evolving market.
Is the company independently operated, or is it owned by a parent company or investor group with its own uncertain trajectory? A recently changed ownership structure is only as stable as the new owner's strategic commitment and financial resources.
Has the company experienced layoffs, leadership turnover, ownership changes, or restructuring in the last 12 months? These are typically leading indicators of operational instability, not lagging ones.
Is the company's GLP-1 program its primary business, or a secondary offering? Companies whose primary business is something other than GLP-1 telehealth may deprioritize or restructure their GLP-1 offering if it underperforms relative to their core business.
Can the company provide specific assurances about service continuity? A stable provider can say clearly: "We are currently accepting new patients, our program structure is not changing, and we have the operational capacity to support your treatment for the next 12 to 18 months." If a provider hedges or deflects on these questions, that is meaningful information.
No ownership drama.
Just flat, predictable pricing.
Compounded semaglutide $197/month flat. VialsRX pharmacy (TX Board #35264). No contracts. Wasef Health, PC clinical oversight.
Start With Luma Health →Frequently Asked Questions
Between the two, Hims is the more operationally stable choice as of June 2026. Hims is a standalone publicly traded company with an established, scaled GLP-1 program. Lemonaid Health has genuine clinical strengths — it was built with a more substantive clinical model than many consumer-facing telehealth brands — but it changed ownership entirely in 2025 after its former parent, 23andMe, went through bankruptcy, and now operates under a newer, smaller ownership group. For patients seeking a third option with flat-rate pricing, publicly verifiable pharmacy credentials, and no recent corporate upheaval, Luma Health ($197/month flat for semaglutide) is a strong alternative to both.
As of June 2026, Lemonaid Health continues to operate and offer telehealth services including GLP-1 prescriptions, now under new ownership (Bambu Ventures and Innova Capital Partners) after being sold out of 23andMe's 2025 bankruptcy. Program availability, pricing, and clinical team composition should be verified directly with Lemonaid before enrolling, since the ownership transition is still relatively recent and terms may continue to evolve.
23andMe acquired Lemonaid Health in November 2021 for approximately $400 million. 23andMe subsequently experienced a major data breach, stock collapse, and repeated layoffs, culminating in a Chapter 11 bankruptcy filing in March 2025. In the bankruptcy proceedings, 23andMe's genetics and research business was sold to Regeneron Pharmaceuticals for $256 million — a deal that explicitly did not include Lemonaid Health. Lemonaid was sold in a separate, much smaller transaction to Bambu Ventures and Innova Capital Partners for approximately $10 million, a deal that closed in late 2025. Lemonaid now operates independently of 23andMe under this new ownership.
Hims' compounded semaglutide pricing ranges from approximately $79/month at the starting dose to $149 to $199/month at therapeutic maintenance doses, with pricing increasing at each dose tier. Lemonaid Health's GLP-1 program has historically been structured around a membership fee (reported around $49/month) with medication billed separately — verify current total pricing directly given the recent ownership change. For comparison, Luma Health offers compounded semaglutide at $197/month flat regardless of dose tier, with no contracts.
The best alternative depends on what you prioritize. If you want the lowest starting price, Hims ($79/month for the starting dose) remains competitive. If you want flat-rate pricing that does not change as your dose escalates, no contract commitment, and a provider focused exclusively on GLP-1 with publicly verifiable pharmacy credentials, Luma Health ($197/month flat for semaglutide) is a strong alternative to both. For a comprehensive comparison of all major providers on cost, see our cheapest GLP-1 providers ranked guide.
Hims offers compounded tirzepatide as part of its weight loss program, typically priced at approximately $199 to $329/month. Lemonaid Health's tirzepatide availability should be verified directly given the program's recent ownership transition. Luma Health offers compounded tirzepatide at $297/month flat — the same active ingredient as Zepbound and Mounjaro — with no dose-tier increases and free shipping to all 50 states.
Yes. Switching GLP-1 providers mid-treatment is clinically straightforward because the active ingredient is the same across providers and no washout period is required. The correct sequence is to enroll with Luma Health first, wait for prescription approval and confirm your shipping timeline, then cancel your current provider. Your Luma Health provider will prescribe at your current dose level — you do not restart titration. Use your remaining supply from your previous provider until your Luma Health medication arrives, then switch at your next scheduled injection day.
Lemonaid Health's GLP-1 program, like most compounded GLP-1 telehealth programs, is a cash-pay service that does not accept insurance for the membership or compounded medication costs. Hims and Luma Health also operate on cash-pay models for their GLP-1 programs. HSA or FSA funds may be applicable depending on your account administrator's policies — verify eligibility with your specific account administrator before planning to use these funds.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Rubino DM, et al. Effect of Continued Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. PubMed 33755728
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA.gov — Wegovy PI
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- CNBC. Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million. May 19, 2025. CNBC.com
- Crunchbase News. Why This VC Firm Bought Telemedicine Company Lemonaid Out Of The 23andMe Bankruptcy. October 2025. news.crunchbase.com
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov